A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Oxigene Therapeutics

About Oxigene

OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company’s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. Oxigene's flagship compound is Combretastatin CA4 Prodrug


Pieline for Oxigene


Combretastatin CA4 -- Combretastatin represents a new class of therapeutic compounds known as vascular targeting agents. These agents may be useful in disease conditions or pathologies such as cancer, where an abnormal growth of blood vessels is an essential component to the disease and its progression. Combretastatin has shown the ability in both preclinical animal model and clinical trials to drastically reduce blood flow in tumors.


CA4P -- Anaplastic Thyroid Cancer; Imageable Tumors


More on Oxigene


Home Page

Key Statistics for Oxigene

Basic Chart for Oxigene

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.